Gene Therapy for Inherited Retinal Degeneration

Area of Science:

• Ophthalmology
• Genetics
• Molecular Biology

Background:

• Inherited retinal degeneration (IRD) causes progressive photoreceptor cell loss.
• IRDs exhibit diverse inheritance patterns: autosomal dominant (AD), autosomal recessive (AR), X-linked (XL), and mitochondrial.
• Current treatments are limited, necessitating novel therapeutic approaches.

Purpose of the Study:

• To review current ocular gene therapy strategies for IRDs.
• To discuss gene augmentation and gene disruption techniques.
• To highlight the role of gene editing tools, particularly CRISPR/Cas, in IRD treatment.

Main Methods:

• Review of existing literature on ocular gene therapy for IRDs.
• Analysis of gene augmentation strategies using viral and nonviral vectors.
• Examination of gene disruption methods, including CRISPR/Cas systems.

Main Results:

• Gene augmentation effectively treats AR, XL, and some AD IRDs by introducing functional gene copies.
• Gene disruption is a viable strategy for AD IRDs with gain-of-function or dominant-negative mutations.
• Viral and nonviral vectors are employed for gene delivery in vitro and in vivo.

Conclusions:

• Ocular gene therapy presents promising treatment avenues for IRDs.
• Gene augmentation and gene editing offer distinct therapeutic approaches based on IRD genetics.
• CRISPR/Cas technology shows significant potential for precise genetic correction in IRDs.